Yang Wei, Woodgate Roger
National Institute of Diabetes and Digestive and Kidney Diseases and Laboratory of Genomic Integrity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15591-8. doi: 10.1073/pnas.0704219104. Epub 2007 Sep 26.
Living organisms are continually under attack from a vast array of DNA-damaging agents that imperils their genomic integrity. As a consequence, cells possess an army of enzymes to repair their damaged chromosomes. However, DNA lesions often persist and pose a considerable threat to survival, because they can block the cell's replicase and its ability to complete genome duplication. It has been clear for many years that cells must possess a mechanism whereby the DNA lesion could be tolerated and physically bypassed. Yet it was only within the past decade that specialized DNA polymerases for "translesion DNA synthesis" or "TLS" were identified and characterized. Many of the TLS enzymes belong to the recently described "Y-family" of DNA polymerases. By possessing a spacious preformed active site, these enzymes can physically accommodate a variety of DNA lesions and facilitate their bypass. Flexible DNA-binding domains and a variable binding pocket for the replicating base pair further allow these TLS polymerases to select specific lesions to bypass and favor distinct non-Watson-Crick base pairs. Consequently, TLS polymerases tend to exhibit much lower fidelity than the cell's replicase when copying normal DNA, which results in a dramatic increase in mutagenesis. Occasionally this can be beneficial, but it often speeds the onset of cancer in humans. Cells use both transcriptional and posttranslational regulation to keep these low-fidelity polymerases under strict control and limit their access to a replication fork. Our perspective focuses on the mechanistic insights into TLS by the Y-family polymerases, how they are regulated, and their effects on genomic (in)stability that have been described in the past decade.
生物体不断受到大量DNA损伤剂的攻击,这些损伤剂危及它们的基因组完整性。因此,细胞拥有一大批酶来修复受损的染色体。然而,DNA损伤常常持续存在,并对细胞存活构成相当大的威胁,因为它们会阻碍细胞的复制酶及其完成基因组复制的能力。多年来人们已经清楚地认识到,细胞必须拥有一种机制,通过这种机制可以耐受DNA损伤并在物理上绕过它。然而,直到过去十年,用于“跨损伤DNA合成”或“TLS”的特殊DNA聚合酶才被鉴定和表征。许多TLS酶属于最近描述的DNA聚合酶“Y家族”。通过拥有一个宽敞的预形成活性位点,这些酶可以在物理上容纳各种DNA损伤并促进其绕过。灵活的DNA结合结构域和用于复制碱基对的可变结合口袋进一步使这些TLS聚合酶能够选择特定的损伤进行绕过,并有利于形成独特的非沃森-克里克碱基对。因此,TLS聚合酶在复制正常DNA时的保真度往往比细胞的复制酶低得多,这导致突变率急剧增加。偶尔这可能是有益的,但它常常加速人类癌症的发生。细胞利用转录和翻译后调控来严格控制这些低保真度聚合酶,并限制它们接近复制叉。我们的观点聚焦于过去十年中对Y家族聚合酶介导的TLS的机制性见解、它们是如何被调控的,以及它们对基因组(不)稳定性的影响。